|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Han B, Zheng R, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2022. J Natl Cancer Cent. 4:47–53. 2024.PubMed/NCBI
|
|
3
|
Zhou H, Liu Z, Wang Y, Wen X, Amador EH,
Yuan L, Ran X, Xiong L, Ran Y, Chen W and Wen Y: Colorectal liver
metastasis: Molecular mechanism and interventional therapy. Signal
Transduct Target Ther. 7:702022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kiemer AK, Takeuchi K and Quinlan MP:
Identification of genes involved in epithelial-mesenchymal
transition and tumor progression. Oncogene. 20:6679–6688. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shin AE, Giancotti FG and Rustgi AK:
Metastatic colorectal cancer: Mechanisms and emerging therapeutics.
Trends Pharmacol Sci. 44:222–236. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Kornmann M and Traub B: Role of
epithelial to mesenchymal transition in colorectal cancer. Int J
Mol Sci. 24:148152023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vu T and Datta P: Regulation of EMT in
colorectal cancer: A culprit in metastasis. Cancers. 9:1712017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Francí C, Gallén M, Alameda F, Baró T,
Iglesias M, Virtanen I and García de Herreros A: Snail1 protein in
the stroma as a new putative prognosis marker for colon tumours.
PLoS One. 4:e55952009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan X, Yan L, Liu S, Shan Z, Tian Y and
Jin Z: N-cadherin, a novel prognostic biomarker, drives malignant
progression of colorectal cancer. Mol Med Rep. 12:2999–3006. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Du L, Li J, Lei L, He H, Chen E, Dong J
and Yang J: High vimentin expression predicts a poor prognosis and
progression in colorectal cancer: A study with meta-analysis and
TCGA database. Biomed Res Int. 2018:1–14. 2018. View Article : Google Scholar
|
|
15
|
Mashima R and Okuyama T: The role of
lipoxygenases in pathophysiology; New insights and future
perspectives. Redox Biol. 6:297–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Wang W, Sanidad KZ, Shih PA, Zhao
X and Zhang G: Eicosanoid signaling in carcinogenesis of colorectal
cancer. Cancer Metastasis Rev. 37:257–267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Soumaoro LT, Iida S, Uetake H, Ishiguro M,
Takagi Y, Higuchi T, Yasuno M, Enomoto M and Sugihara K: Expression
of 5-lipoxygenase in human colorectal cancer. World J
Gastroenterol. 12:6355–6360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Melstrom LG, Bentrem DJ, Salabat MR,
Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA,
Talamonti MS, et al: Overexpression of 5-lipoxygenase in colon
polyps and cancer and the effect of 5-LOX inhibitors in vitro and
in a murine model. Clin Cancer Res. 14:6525–6530. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang J, Tang N, Fang Q, Zhu K, Liu L,
Xiong X, Zhu Z, Zhang B, Zhang M and Tao J: Inhibition of COX-2 and
5-LOX regulates the progression of colorectal cancer by promoting
PTEN and suppressing PI3K/AKT pathway. Biochem Biophys Res Commun.
517:1–7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bošković J, Dobričić V, Keta O, Korićanac
L, Žakula J, Dinić J, Jovanović Stojanov S, Pavić A and Čudina O:
Unveiling anticancer potential of COX-2 and 5-LOX inhibitors:
Cytotoxicity, radiosensitization potential and antimigratory
activity against colorectal and pancreatic carcinoma.
Pharmaceutics. 16:8262024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Z, Zhang X, Bai X, Xi X, Liu W and
Zhong W: Anti-angiogenesis in colorectal cancer therapy. Cancer
Sci. 115:734–751. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tello-Montoliu A, Patel JV and Lip GY:
Angiogenin: A review of the pathophysiology and potential clinical
applications. J Thromb Haemost. 4:1864–1874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69:4–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arocho A, Chen B, Ladanyi M and Pan Q:
Validation of the 2-DeltaDeltaCt calculation as an alternate method
of data analysis for quantitative PCR of BCR-ABL P210 transcripts.
Diagn Mol Pathol. 15:56–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rådmark O, Werz O, Steinhilber D and
Samuelsson B: 5-Lipoxygenase, a key enzyme for leukotriene
biosynthesis in health and disease. Biochim Biophys Acta.
1851:331–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hennig R, Ding XZ, Tong WG, Schneider MB,
Standop J, Friess H, Büchler MW, Pour PM and Adrian TE:
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human
pancreatic cancers but not in pancreatic ducts in normal tissue. Am
J Pathol. 161:421–428. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gupta S, Srivastava M, Ahmad N, Sakamoto
K, Bostwick DG and Mukhtar H: Lipoxygenase-5 is overexpressed in
prostate adenocarcinoma. Cancer. 91:737–743. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Wang S, Wu N, Sood S, Wang P, Jin
Z, Beer DG, Giordano TJ, Lin Y, Shih WC, et al: Overexpression of
5-lipoxygenase in rat and human esophageal adenocarcinoma and
inhibitory effects of zileuton and celecoxib on carcinogenesis.
Clin Cancer Res. 10:6703–6709. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kennedy BM and Harris RE: Cyclooxygenase
and lipoxygenase gene expression in the inflammogenesis of
colorectal cancer: Correlated expression of EGFR, JAK STAT and Src
genes, and a natural antisense transcript, RP11-C67.2.2. Cancers.
15:23802023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu WM, Liu SQ, Zhu KF, Li W, Yang ZJ, Yang
Q, Zhu ZC and Chang J: The ALOX5 inhibitor Zileuton regulates
tumor-associated macrophage M2 polarization by JAK/STAT and
inhibits pancreatic cancer invasion and metastasis. Int
Immunopharmacol. 121:1105052023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Steinhilber D, Fischer AS, Metzner J,
Steinbrink SD, Roos J, Ruthardt M and Maier TJ: 5-Lipoxygenase:
Underappreciated role of a pro-inflammatory enzyme in
tumorigenesis. Front Pharmacol. 1:1432010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang N, Ng AS, Cai S, Li Q, Yang L and
Kerr D: Novel therapeutic strategies: Targeting
epithelial-mesenchymal transition in colorectal cancer. Lancet
Oncol. 22:e358–e368. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim TY, Kim J, Choo HY and Kwon HJ:
Inhibition of 5-lipoxygenase suppresses vascular endothelial growth
factor-induced angiogenesis in endothelial cells. Biochem Biophys
Res Commun. 478:1117–1122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic
effects of melatonin in endothelial cell cultures. Microvasc Res.
87:25–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng J, Yang HL, Gu CJ, Liu YK, Shao J,
Zhu R, He YY, Zhu XY and Li MQ: Melatonin restricts the viability
and angiogenesis of vascular endothelial cells by suppressing
HIF-1α/ROS/VEGF. Int J Mol Med. 43:945–955. 2019.PubMed/NCBI
|
|
37
|
Gacche RN and Meshram RJ: Targeting tumor
micro-environment for design and development of novel
anti-angiogenic agents arresting tumor growth. Prog Biophys Mol
Bio. 113:333–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kishimoto K, Liu S, Tsuji T, Olson KA and
Hu GF: Endogenous angiogenin in endothelial cells is a general
requirement for cell proliferation and angiogenesis. Oncogene.
24:445–456. 2005. View Article : Google Scholar : PubMed/NCBI
|
